Biocon Biologics recognized as an Asia IP Elite for 2023

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list

Dr. Reddy's becomes first Indian pharma company to debut on the DJSI

Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis

Zydus inks licensing agreement with Daewoong Pharmaceutical for leuprolide injectable in the US

The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome

Max Healthcare acquires 550 bedded Sahara Hospital, Lucknow

This acquisition marks Max Healthcare's entry into Lucknow

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya

Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets

This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa

Syngene concludes acquisition of biologics manufacturing facility from Stelis Biopharma

The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene

Aster to separate its India and GCC businesses to unlock value

Both the India and GCC entities will be operated by separate dedicated management teams

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India

Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain